What development phase is Calvan in?

Calvan is FDA-approved (marketed).

What is the generic name of Calvan?

BEVANTOLOL is the generic (nonproprietary) name of Calvan.

Last reviewed 2026-04-20 · How we verify

Calvan (BEVANTOLOL)

FDA-approved active Small molecule Quality 15/100

Calvan (bevantolol) is a small molecule drug that targets the beta-1 adrenergic receptor. It is a non-selective beta blocker, but its exact indications and commercial status are unknown. As a bevantolol, it works by blocking the effects of the hormone epinephrine, which can help to slow the heart rate and reduce blood pressure. However, more information is needed to fully understand its clinical use and availability. Further research is required to determine its current status in the pharmaceutical market.

At a glance

Generic name	BEVANTOLOL
Drug class	bevantolol
Target	Beta-1 adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety on SOM3355 in Huntington's Disease Chorea (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Calvan CI brief — competitive landscape report
Calvan updates RSS · CI watch RSS